Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Provides Updates Regarding its Board of Directors
CELEBRATION, Fla. , Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that, on September 18, 2019 , Danny L. Thompson provided notice of his resignation from the
Toggle Summary KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
CELEBRATION, Fla. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
Toggle Summary KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
CELEBRATION, Fla. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its president and chief executive officer, Travis C.
Toggle Summary KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audio Webcast with Slide Presentation Today, Wednesday, September 4, 2019 , at 10:00 a.m. ET CELEBRATION, Fla. , Sept.
Toggle Summary KemPharm Reports Second Quarter 2019 Results
CELEBRATION, Fla. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter ended June 30, 2019 .
Toggle Summary KemPharm Reports First Quarter 2019 Results
Development & Regulatory Highlights: Completed KP415 Pre-NDA Meeting with FDA Provided Update on APADAZ ® Formulary Adoption Announced FDA Approval of sNDA for Two Additional Strengths of APADAZ Corporate & Financial Highlights: Q1 2019 net loss of $0.46 per basic and diluted share Total cash, cash
Toggle Summary KemPharm Completes KP415 Pre-NDA Meeting with FDA
KP415 NDA Filing Anticipated in Late Q2 or Early Q3 2019 Conference Call Scheduled for Today, Thursday, April 11, 2019 at 5:00 p.m. ET CELEBRATION, Fla. , April 11, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of
Toggle Summary KemPharm Provides Update on APADAZ® Formulary Adoption
Conference Call Scheduled for Today, Wednesday, March 13, 2019 at 8:30 a.m. ET Highlights: According to MMIT estimates, the authorized generic for APADAZ has unrestricted formulary access for 91% of Commercial lives and unrestricted access for 90% of state Medicaid lives According to MMIT
Toggle Summary KemPharm to Present at Upcoming Investor Conferences
CELEBRATION, Fla. , March 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that management will present at several investor conferences during March 2019 .
Toggle Summary KemPharm Reports Q4 and FY 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Completed KP415 clinical and human abuse potential programs Received approval of APADAZ ® Enhanced pipeline with the addition of KP879, a potential new treatment